Aim: Little is known about the patterns of care and the impact of hepatocellular carcinoma (HCC) treatment on health outcomes at a population level. We conducted a population-based cohort study to examine HCC survival trends among people diagnosed with hepatitis B (HBV) or hepatitis C virus (HCV) infection, to determine predictors of receiving potentially curative therapy for HCC, and to examine the impact of HCC treatment on survival in New South Wales, Australia.
Methods: The KaplanMeier method was used to estimate survival, logistic regression to determine predictors of potentially curative therapy and Cox proportional hazards models to determine the impact of HCC treatment on survival. Years of potential life lost (YPLL) were calculated.
Results: During the period 19932007, 1081 cases of HCC were diagnosed. Median survival increased from 10.4 months during 19931997 to 18.4 months during 19982002, with no further improvement thereafter. Younger age at diagnosis (
Conclusion: The burden of viral hepatitis-related HCC is substantial. Despite treatment advances in recent years, there has been no significant improvement in HCC survival. Efforts to improve HCC screening and early diagnosis are required to deliver curative treatment which clearly has a survival advantage.
- hepatitis B virus
- hepatitis C virus
- hepatocellular carcinoma
- treatment outcome